<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/2CFCE99B-9E97-4473-9E9F-E4EA91BB2D45"><gtr:id>2CFCE99B-9E97-4473-9E9F-E4EA91BB2D45</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Thomas</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U117560890"><gtr:id>A207DD48-211B-43B7-9F35-30006508ACE7</gtr:id><gtr:title>Development of a generic conditional-lethal transgene for development studies of the immune system</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U117560890</gtr:grantReference><gtr:abstractText>We have shown that a viral protein, if present in mammalian cells following genetic manipulation, results in rapid cell death. The protein is present on the surface of the cell, forms a channel that allows entry/exit of small ions that is lethal. The channel can be blocked by an anti-viral drug which rescues cell viability. This provides a means for molecular subtraction whereby we can identify molecules that are present in drug-treated cells and absent from untreated cells. We have produced genetically-manipulated mice in which the toxic gene is expressed during early lymphoid development. As a result, such transgenic mice lack an immune system. However, lymphoid development, in the foetus can be rescued by drug-treatment. This may provide a means of identifying novel regulatory molecules that are expressed at a defined point of early lymphoid development.</gtr:abstractText><gtr:technicalSummary>1. General Aims Relevance Health Issues. To identify molecular mechanisms that regulate early lymphoid development. Such regulatory factors of relevance to both normal lymphoid development and leukaemia. 2. Precise Scientific Objectives. To identify novel transcription factors that are expressed at a defined point in early lymphoid development. 3. Plan of Investigation. We have shown that a novel viral ion channel, if expressed as a transgene under control of a lymphocyte specific promoter results in total ablation of lymphoid development at a defined point in the foetus, and toxicity can be blocked by a drug that inhibits ion channel activity. A subtractive procedure has been developed to identify novel mRNA species that are present in drug-treated foetal tissues (and absent from untreated) and whose expression is restricted to this time in embryonic development. 4. Subsequent Scientific/Medical Opportunities. The ion channel transgene provides a generic protocol that may be employed in any developmental study. 5. Key Words. Viral ion channel; conditional-lethal transgene; lymphoid development; T-cell; thymopoiesis.</gtr:technicalSummary><gtr:fund><gtr:end>2006-09-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1999-10-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>175843</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">MC_U117560890</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>80</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>